Similarly in H1437 and H1944 NSCLC cell lines, ERK1/2 inhibitor abrogated the volasertib-induced PD-L1 upregulation, while NF-kB inhibition had no effect (Supplementary Fig. 5). The gene discussed is NFKB1; the disease is non-small cell lung carcinoma.